Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated.

Trial Profile

Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Capecitabine; Sunitinib
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top